Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease

Lorenzo Cavagna, Roberto Caporali, Lul Abdi-Alì, Roberto Dore, Federica Meloni, and Carlomaurizio Montecucco

ABSTRACT. Objective. To describe the longterm effectiveness and safety of cyclosporine (CYC) in patients with anti-Jo1-positive antisynthetase syndrome with corticosteroid-refractory interstitial lung disease (ILD).

Methods. All patients with anti-Jo1 antisynthetase syndrome referred to our division between June 1991 and February 2010 were retrospectively evaluated for ILD. ILD was assessed using pulmonary function tests (PFT) and/or high-resolution computed tomography (HRCT). Kazerooni score was used to evaluate the HRCT extent of ILD. Prednisone was the first-line treatment in all cases (1 mg/kg/day orally, then tapering). Patients with corticosteroid-refractory or relapsing ILD were then included in this retrospective study. All patients started CYC (3 mg/kg/day) without increasing prednisone dosage. Both PFT and chest HRCT were regularly reassessed during followup.

Results. Over the period of study we evaluated 18 patients with antisynthetase syndrome; 17 had ILD (13 women; median age at ILD onset 57 yrs); all patients failed prednisone within 12 months of ILD onset and subsequently started CYC. The median followup on CYC was 96 months [inter-quartile range (IQR) 57–120 mo]. Upon starting CYC, median forced vital capacity (FVC) was 60% (IQR 56%–70%), median DLCO 60% (IQR 50%–62.75%), and median Kazerooni score 16 (IQR 7–18). After 1 year of CYC, FVC (p = 0.0006), DLCO (p = 0.0010), and total Kazerooni score (p = 0.0002) improved and prednisone was tapered (median reduced from 25 mg/day to 2.5 mg/day; p < 0.0001). The results were substantially maintained including at last available followup. CYC side effects were hypertension (5 patients) and creatinine increase (6 patients). CYC was reduced in 3 cases and withdrawn in 4. Three out of 4 patients who interrupted CYC experienced ILD relapse; 2 patients recommenced low-dose CYC with subsequent ILD control. One patient refused re-treatment and subsequently died.

Conclusion. CYC is effective and substantially safe in patients with anti-Jo1 antisynthetase syndrome with corticosteroid-refractory ILD. CYC withdrawal may be associated with ILD relapse, and low-dose CYC was effective in ILD control. (First Release Feb 15 2013; J Rheumatol 2013;40:484–92; doi:10.3899/jrheum.121026)

Key Indexing Terms:
ANTI-JO1 ANTISYNTHETASE SYNDROME INTERSTITIAL LUNG DISEASE CORTICOSTEROID-REFRACTORY CYCLOSPORINE

Aminoacyl-tRNA synthetases are a group of cytoplasmic enzymes that catalyze aminoacyl-tRNA synthesis and thus protein synthesis. The antibodies linked to these enzymes are the serological markers of a rare subset of polymyositis/dermatomyositis (PM/DM), characterized by the occurrence of Raynaud phenomenon, peripheral arthritis, typical cutaneous manifestations (e.g., mechanic’s hands), and interstitial lung disease (ILD): the antisynthetase syndrome. Among the different antisynthetase antibodies, histidyl-tRNA (anti-Jo1) is the most common target, being found in up to 20% of patients with PM/DM. Other antibodies are directed against the aminoacyl-tRNA synthetase for threonine (PL-7), alanine (PL-12), glycine (E3), asparagine (K5), and isoleucine (O). Pulmonary fibrosis is observed in up to 85% of patients with antisynthetase syndrome, a much higher frequency than in classic PM/DM. Therefore, ILD in antisynthetase syndrome is different from that commonly described in PM/DM not only in prevalence, but also due to other peculiarities, as suggested by previous proteomic studies. ILD is the major determinant of morbidity and mortality in antisynthetase syndrome in general and in patients with anti-PL7 and anti-PL12 specificities in particular.
The treatment is still a matter of debate. Although (as for PM/DM-related ILD) corticosteroids have been considered the mainstay treatment, their effectiveness in monotherapy is generally limited and unsatisfactory. Immunosuppressants are frequently prescribed because of refractory/relapsing ILD, as recently observed by Stanciu, et al in one of the largest cohorts of anti-Jo1 patients yet described. To date, therapies such as cyclophosphamide and azathioprine have yielded contrasting results. Other immunosuppressants have been used in single case reports or small pilot studies. Good results were obtained with leflunomide, mycophenolate, rituximab, anakinra, and in particular, tacrolimus, which acts as a calcineurin inhibitor and principally affects T lymphocytes. Cyclosporine (CYC) is another calcineurin inhibitor found to be effective in PM/DM-related ILD and also in limited series/case reports of antisynthetase syndrome patients with ILD. We describe our observations regarding the longterm effectiveness and safety of CYC for treatment of patients with anti-Jo1 antisynthetase syndrome with corticosteroid-refractory/relapsing ILD.

MATERIALS AND METHODS

Patients. All patients referred to our division between June 1991 and February 2010 with a diagnosis of anti-Jo1-positive antisynthetase syndrome were retrospectively reevaluated for ILD occurrence. Only the patients with corticosteroid-refractory or relapsing ILD were included in our study. In all cases, clinical features and complete investigation results (biochemical and instrumental) were available from disease onset. Autoantibody profiling. Anti-Jo1 positivity was reassessed for confirmation on frozen and stored serum from all patients and additional anti-extractable nuclear antigen specificities were also tested for on the same samples by EliA fluorescence-immunoassay (Phadia 250 automatic instrumentation, Phadia GmbH).

Pulmonary function tests (PFT). A Vmax 22 system and an Autobox V6200 (SensorMedics) were used to measure lung function. For spirometry, mouth flow was measured using a mass flow sensor and volume was obtained by numerical integration of the flow signal. After at least 4 stable tidal breaths, patients were asked to exhale slowly to residual volume and to then inhale forcefully to total lung capacity. This maneuver was immediately followed by a forced expiration to residual volume. The forced inspiratory flow at 50% of FVC and forced expiratory flows at 50% and 25% of FVC were measured on flow-volume curves. Forced expiratory maneuvers were repeated until reproducible values of forced expiratory volume in 1 s (FEV1) and FVC were obtained.

Lung volumes were measured with patients sitting in a body plethysmograph and panting against a closed shutter at a frequency of 1 Hz with their cheeks supported. Predicted values for spirometry and lung volumes were provided by Quanjer, et al. The single-breath technique, according to a modified Krogh procedure, was used to determine DLCO.

High-resolution computed tomography (HRCT) of the chest. HRCT was performed using the conventional sequential technique from 1991 to 2003, using the 16-detector spiral technique from 2003 to 2008 and the 64-detector technique from 2008 to 2011. With the sequential technique, about 10 slices were obtained in each examination, with 1 mm thickened, 10 mm interscan space, and about 1–2 mSV radiation dose. With the spiral technique, a volumetric acquisition was obtained and axial and coronal images were reformatted with 1–1.2 mm thickened. Automatic modulation of photon energy and radiation doses depended on patient size and anatomical region. The usual energy and radiation dose was used for baseline CT examination (about 3–4 mSv), while low energy (80–100 Kv instead of 120 Kv) was used in followup studies (about 2–3 mSv). Anti-X screening was used on the skin of all patients studied from 2010, to protect breasts, thyroid, and crystalline lenses.

Clinical and instrumental assessment. We defined the presentation of ILD as acute/subacute when dyspnea began acutely and progressed rapidly (within 4–6 weeks of symptom onset), chronic when dyspnea began insidiously and progressed slowly, and asymptomatic when lung involvement was only instrumental and there were no clinical correlates. Instrumentally, lung involvement was defined by a restrictive PFT pattern (FVC < 80%, FEV1/FVC < 70%, decreased or normal FEV1, and/or < 20% reduction in DLCO) and/or by signs of alveolitis/fibrosis on HRCT. We routinely performed PFT every 2 months in all cases until well established disease improvement/stabilization was reported, then every 6 months thereafter. Chest HRCT was carried out at onset and then every 12 months thereafter or in the case of ILD worsening. A well established and commonly used score, the Kazerooni score, was used to evaluate the extent of ILD at baseline and during followup. This entails scoring each lobe of the lung on a scale of 0–5 for both alveolar (e.g., ground-glass alterations) and interstitial abnormality (e.g., fibrotic lesions such as honeycombing and septal lines) depending on the percentage of each lobe involved and the type of finding observed. The pattern of interstitial involvement was evaluated by HRCT according to American Thoracic Society/European Respiratory Society classification criteria. Kazerooni score and ILD pattern were assessed by our reference radiologist (RD). ILD was considered refractory (or relapsing) in cases of worsening dyspnea, more than 10% FVC or DLCO deterioration compared to either previous or basal tests, and/or when Kazerooni score progressed, even when FVC and DLCO were stable.

Treatment. Initially, all patients were treated with prednisone orally 1 mg/kg/day for at least 1 month; prednisone dosage was then progressively tapered according to clinical/instrumental effectiveness, as previously described. Patients with worsening or relapsing ILD were given CYC (3 mg/kg/day) as additional treatment without increasing the prednisone, which remained unchanged until ILD was under control. In all cases, a clinical and biochemical evaluation was performed every 2 months; CYC dosage was reduced in cases reporting a creatinine increase > 30% compared to baseline values or in the case of uncontrolled arterial hypertension.

Statistical analysis. Data were expressed as median and interquartile range (IQR). FVC, DLCO, Kazerooni score, and prednisone dosages at baseline, after 1 year, and at the last available followup with CYC were compared and analyzed by the paired-samples t-test. Stata 10.1 (Stata Corp.) was used for computation. A 2-sided p-value < 0.050 was considered statistically significant.

RESULTS

From June 1991 to February 2010 we observed 18 patients with anti-Jo1-positive antisynthetase syndrome. Of those patients, 17 showed evidence of ILD according to the selection criteria. All these patients were retrospectively reassessed; ILD onset was acute in 7 cases and chronic in 10 and no patients had asymptomatic ILD. Each of these 17 patients had failed to respond to prednisone within 12 months prior to starting CYC. The median age at ILD onset was 57 years (IQR 49–69). Patients’ demographic data and main clinical features are reported in Table 1. HRCT pattern of ILD was consistent with nonspecific interstitial pneumonia in 14 patients and with usual interstitial pneumonia (UIP) in 3; we observed a discrete entity of ground-glass opacities besides honeycombing and reticulation in patients with UIP.
CYC was started 2 months after initiation of corticosteroid therapy in 8 patients (corticosteroid-refractory ILD). In all cases, baseline values of FVC or DLCO worsened and clinical respiratory status deteriorated. However, Kazerooni score was stable in 5 patients and progressed in 3. The remaining patients improved soon after starting prednisone but worsened subsequently (in PFT and clinically). Four patients started CYC 6 months after starting corticosteroid therapy and 5 patients 12 months after starting corticosteroid therapy (relapsing ILD). The Kazerooni score of those patients progressed in 3 and 4 cases, respectively, and was stable in the remaining patients (data not shown).

When CYC was started, all patients had dyspnea and 4 needed O₂ treatment at rest. Other antisynthetase syndrome manifestations were usually effectively controlled by corticosteroids. FVC was reduced in 13 patients (median 60% of predicted value, IQR 56–70), while all patients had DLCO reduction (median 60% of predicted value, IQR 50–62.75). The median Kazerooni score was 16 (IQR 7–18).

During the first year of treatment, a significant improvement was reported in FVC (median 75% of theoretical value, IQR 67–85; p = 0.0006), DLCO (median 66% of theoretical value, IQR 57.25–72.25; p = 0.0010), and total Kazerooni score (median 10, IQR 4–15; p = 0.0002) because of reduction of ground-glass opacity. In 2 patients with HRCT pattern of UIP, the reduction of ground-glass opacities, while evident, was not sufficient to reduce the Kazerooni score. Prednisone was therefore tapered to a median value of 25 mg/day (IQR 12.5–50).

After initiation of CYC, O₂ therapy was discontinued within 2 months in 2 patients (Patients 1 and 14) but continued in 2 cases, although it was reduced from 4 l/min to 1 l/min (Patients 2 and 5). During the first year of the study, all patients were responsive to CYC and their respiratory symptoms improved. During the first year of followup, other systemic disease manifestations were effectively controlled. At 1 year of treatment, a significant improvement was reported in FVC (median 75% of theoretical value, IQR 67–85; p = 0.0006), DLCO (median 66% of theoretical value, IQR 57.25–72.25; p = 0.0010), and total Kazerooni score (median 10, IQR 4–15; p = 0.0002) because of reduction of ground-glass opacity. In 2 patients with HRCT pattern of UIP, the reduction of ground-glass opacities, while evident, was not sufficient to reduce the Kazerooni score. Prednisone was therefore tapered to a median value of 25 mg/day (IQR 2.5–5; p < 0.0001).

In the subsequent years, 5 patients (Patients 4, 5, 8, 14, CYC was started, median prednisone dosage was 25 mg/day (IQR 12.5–50).

Table 1. Baseline characteristics and progression of patients.

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex, Age at ILD onset</th>
<th>Serology</th>
<th>Disease Duration Before CYC, mo</th>
<th>Other Typical Antisynthetase-related Features</th>
<th>ILD Pattern (HRCT)</th>
<th>ILD Onset</th>
<th>CYC, mo</th>
<th>CYC Side Effects</th>
<th>CYC Dose start/last, mg/kg/day</th>
<th>PDN Dose at CYC start/last, mg/kg/day</th>
<th>O₂ Therapy, l/min, start/last</th>
<th>Global Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M 74</td>
<td>Jo-1/Ro</td>
<td>6</td>
<td>A,M,RP</td>
<td>NSIP</td>
<td>Chronic</td>
<td>57</td>
<td>Creatinine increase</td>
<td>3/0.5</td>
<td>12.5/5</td>
<td>4/0</td>
<td>Dead (car crash)*</td>
</tr>
<tr>
<td>2</td>
<td>M 49</td>
<td>Jo-1/Ro</td>
<td>12</td>
<td>A,RPMH</td>
<td>NSIP</td>
<td>Acute</td>
<td>80</td>
<td>Creatinine increase</td>
<td>3/0.5</td>
<td>10/5</td>
<td>4/1</td>
<td>Lost to followup (associated PAH under CYC)</td>
</tr>
<tr>
<td>3</td>
<td>F 57</td>
<td>Jo-1</td>
<td>12</td>
<td>A,M</td>
<td>UIP</td>
<td>Chronic</td>
<td>72</td>
<td>Creatinine increase</td>
<td>3/1.5</td>
<td>10/2.5</td>
<td>—</td>
<td>Lost to followup</td>
</tr>
<tr>
<td>4</td>
<td>F 69</td>
<td>Jo-1</td>
<td>6</td>
<td>A,M</td>
<td>NSIP</td>
<td>Acute</td>
<td>96</td>
<td>Hypertension</td>
<td>3</td>
<td>25/2.5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>5</td>
<td>F 72</td>
<td>Jo-1/Ro</td>
<td>2</td>
<td>A,M,RPMH</td>
<td>NSIP</td>
<td>Acute</td>
<td>108</td>
<td>Creatinine increase</td>
<td>3/1.5</td>
<td>50/5</td>
<td>4/1</td>
<td>Alive (associated PAH under CYC)</td>
</tr>
<tr>
<td>6</td>
<td>M 69</td>
<td>Jo-1</td>
<td>12</td>
<td>A</td>
<td>NSIP</td>
<td>Chronic</td>
<td>120</td>
<td>Creatinine increase</td>
<td>3/0.5</td>
<td>12.5/2.5</td>
<td>—</td>
<td>Alive* (A under CYC)</td>
</tr>
<tr>
<td>7</td>
<td>F 71</td>
<td>Jo-1</td>
<td>2</td>
<td>A,M</td>
<td>NSIP</td>
<td>Chronic</td>
<td>38</td>
<td>None</td>
<td>3</td>
<td>50/2.5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>8</td>
<td>F 68</td>
<td>Jo-1</td>
<td>2</td>
<td>A,MMH</td>
<td>NSIP</td>
<td>Chronic</td>
<td>144</td>
<td>Hypertension</td>
<td>3</td>
<td>62.5/2.5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>9</td>
<td>M 45</td>
<td>Jo-1</td>
<td>2</td>
<td>A,M</td>
<td>NSIP</td>
<td>Chronic</td>
<td>41</td>
<td>None</td>
<td>3</td>
<td>37.5/—</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>10</td>
<td>F 40</td>
<td>Jo-1/Ro</td>
<td>6</td>
<td>A,M,RPMH</td>
<td>UIP</td>
<td>Chronic</td>
<td>228</td>
<td>None</td>
<td>3</td>
<td>17.5/2.5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>11</td>
<td>F 45</td>
<td>Jo-1</td>
<td>12</td>
<td>A,MMH</td>
<td>NSIP</td>
<td>Acute</td>
<td>96</td>
<td>None</td>
<td>3/0</td>
<td>12.5/2.5</td>
<td>—</td>
<td>Dead (respiratory failure)†</td>
</tr>
<tr>
<td>12</td>
<td>F 72</td>
<td>Jo-1/Ro</td>
<td>12</td>
<td>A,M</td>
<td>NSIP</td>
<td>Chronic</td>
<td>65</td>
<td>None</td>
<td>3</td>
<td>17.5/5</td>
<td>—</td>
<td>Alive (M under CYC)</td>
</tr>
<tr>
<td>13</td>
<td>F 51</td>
<td>Jo-1</td>
<td>6</td>
<td>A,M,RP</td>
<td>NSIP</td>
<td>Chronic</td>
<td>108</td>
<td>None</td>
<td>3</td>
<td>25/5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>14</td>
<td>F 51</td>
<td>Jo-1/Ro</td>
<td>2</td>
<td>A,M,RPMH</td>
<td>NSIP</td>
<td>Acute</td>
<td>192</td>
<td>Creatinine increase</td>
<td>3/0.5</td>
<td>50/5</td>
<td>4/0</td>
<td>Alive</td>
</tr>
<tr>
<td>15</td>
<td>F 58</td>
<td>Jo-1/Ro</td>
<td>2</td>
<td>A</td>
<td>NSIP</td>
<td>Acute</td>
<td>24</td>
<td>None</td>
<td>3</td>
<td>50/2.5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>16</td>
<td>F 49</td>
<td>Jo-1/Ro</td>
<td>2</td>
<td>A,MMH</td>
<td>UIP</td>
<td>Acute</td>
<td>252</td>
<td>Hypertension</td>
<td>3</td>
<td>37.5/2.5</td>
<td>—</td>
<td>Alive</td>
</tr>
<tr>
<td>17</td>
<td>F 50</td>
<td>Jo-1</td>
<td>1</td>
<td>A,M,RP</td>
<td>NSIP</td>
<td>Chronic</td>
<td>30</td>
<td>None</td>
<td>3</td>
<td>37.5/—</td>
<td>—</td>
<td>Alive</td>
</tr>
</tbody>
</table>

* Temporary ILD relapse after short-term CYC withdrawal. † ILD progression after CYC withdrawal. ILD: interstitial lung disease; CYC: cyclosporine; A: arthritis; M: myositis; RP: Raynaud’s phenomenon; PAH: pulmonary arterial hypertension; MH: mechanic’s hands; NSIP: nonspecific interstitial pneumonia; UIP: usual interstitial pneumonia.

**Personal non-commercial use only. The Journal of Rheumatology Copyright © 2013. All rights reserved.**
started low-dose calcium channel blocker treatment because of arterial hypertension, 3 patients reduced CYC (Patients 2, 3, 5), and 3 ceased CYC (Patients 1, 6, 14) because of a rise in creatinine; Patient 11 withdrew from CYC treatment voluntarily and without giving reasons.ILD relapsed in 3 out of 4 patients who stopped CYC (Patients 1, 11, 14); restarting low-dose CYC (0.5 mg/kg/day) in Patients 1 and 14 together with an increase in prednisone dosage (25 mg/day with subsequent tapering) led to ILD control, with no subsequent problems. Patient 11, who spontaneously stopped CYC after 96 months, was lost to followup until a subsequent emergency admission to our division 10 months later with severe acute respiratory failure, which was fatal. There was 1 other death after 57 months of followup, but it was not attributed to antisynthetase syndrome (auto accident). Two patients (Patients 2 and 3) were lost to followup after 80 and 72 months, respectively. At the last eligible followup (median 96 mo, IQR 57–120), FVC (median 81% of theoretical value, IQR 69–89; p = 0.0274) and Kazerooni score (median 9, IQR 4–14; p = 0.0226) had statistically improved, whereas DLCO (median 69% of theoretical value, IQR 55.25–74.5; p = 0.2809) and prednisone (median 2.5 mg/day, IQR 2.5–5; p = 0.1635) were substantially stable compared to 1-year results.

Regarding other disease manifestations, during the longterm followup we observed the appearance of myositis in 1 case (Patient 6, after 21 mo receiving CYC) and arthritis in another (Patient 12, after 24 mo receiving CYC)37. Prednisone was then increased to 25 mg/day in Patient 6 with subsequent tapering, whereas methotrexate (15 mg every week) was added in the case of Patient 12. Treatment was effective in all cases. As described38, we diagnosed pulmonary arterial hypertension in 2 cases (Patients 2 and 5) after 84 and 72 months, respectively, of CYC treatment. The overall characteristics of patients enrolled are given in Table 1. FVC and DLCO fluctuations during the entire period of study are shown in Figure 1. Table 2 reports the mean, SD, median, and IQR of FVC and DLCO in the first 2 years of CYC. Kazerooni score fluctuations during followup are given in Figure 2. The specific findings are shown in Figure 3, which describes PFT changes during followup in patients with UIP.

**DISCUSSION**

Although ILD is a well known manifestation of antisynthetase syndrome, the optimal therapeutic approach in this setting is still debated. Similarly to PM/DM-related ILD, first-line treatment is generally based on corticosteroids8, although second-line drugs are frequently needed because of the high percentage of treatment failure10,11,13,39. Further, the need for immunosuppressants is particularly relevant in anti-Jo1 antisynthetase syndrome with ILD, as confirmed by Stanciu, et al13. Our results substantially confirm the ineffectiveness of corticosteroids alone in this setting, reporting 100% of ILD unresponsiveness or relapse within 12 months of appearance of lung involvement. Regarding second-line drugs, several immunosuppressants have been tried, but only case reports and small pilot studies (without placebo-controlled trials) are available because of the disease’s rarity. Good results have been described with anakinra24, mycophenolate18, and leflunomide17 in single-case reports. Cyclophosphamide and azathioprine have yielded conflicting results; studies have reported both the effectiveness15 and ineffectiveness14,16 of treatments. Moreover, the good results obtained with tacrolimus14 and rituximab22,23 also involved fewer patients than our case series. The maximum length of followup previously reported in similar studies is 36 months in median14. Hence, to our knowledge, ours is the largest and longest study published on the effectiveness of a single immunosuppressant on ILD in antisynthetase syndrome. Moreover, we evaluated only 1 antisynthetase specificity. This may be seen as a strong point of our study because different antisynthetase specificities are associated with different disease profiles7,41,42. Regarding patients’ clinical features, our results are in agreement with those of Hervier, et al7. In fact, anti-Jo1 patients exhibited a wide range of manifestations other than ILD, such as myositis and arthralgias/arthritis. Our data therefore confirm the effectiveness of CYC in this setting. CYC improved not only the clinical respiratory status of all patients and for a long period of time, but also their FVC and DLCO. Further, in comparison to previous studies, our results were reinforced by the reduction of ground-glass opacities, assessed by Kazerooni score34. It is interesting that in the 2 patients with a stable Kazerooni score, we also observed a reduction in ground-glass opacities. The improvement, however, was not significant enough to reduce the score used. These 2 patients had HRCT findings of UIP, characterized by the occurrence of honeycombing and reticulation and, to a lesser extent, by ground-glass opacities. Therefore, in our population, the HRCT pattern described did not influence the evolution of ILD, because patients presenting with UIP were also responsive. However, similar to data given in the literature, the HRCT pattern we found was mainly nonspecific interstitial pneumonia11.

It is also interesting that improvement was observed
when ILD onset was acute and when anti-Ro antibodies, frequently found with anti-Jo1, were detected. Indeed, acute onset and anti-Ro occurrence have been described as negative prognostic factors for ILD progression in antisynthetase syndrome. Moreover, our data showed that patients’ improvement was particularly evident in the first months of therapy with CYC. This could be related to the fast drop in ground-glass opacities soon after starting CYC. The lack of intermediate HRCT controls, however, does not allow us to confirm this hypothesis. It is interesting that both FVC and Kazerooni score were slightly better at the last eligible followup than at 1 year. This indicates the longterm

![Figure 1. Forced vital capacity (top) and DLCO (bottom) fluctuations during cyclosporine treatment (shown as percentage of theoretical value).](image-url)
Table 2. Mean, median, and interquartile range (IQR) of forced vital capacity (FVC) and DLCO during the first 2 years of cyclosporine (CYC) treatment.

<table>
<thead>
<tr>
<th></th>
<th>Basal FVC</th>
<th>Basal DLCO</th>
<th>6 Mo. CYC FVC</th>
<th>6 Mo. CYC DLCO</th>
<th>12 Mo. CYC FVC</th>
<th>12 Mo. CYC DLCO</th>
<th>24 Mo. CYC FVC</th>
<th>24 Mo. CYC DLCO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>65</td>
<td>55</td>
<td>71</td>
<td>60</td>
<td>75</td>
<td>63</td>
<td>76</td>
<td>63</td>
</tr>
<tr>
<td>SD</td>
<td>14</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>12</td>
<td>16</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Median</td>
<td>60</td>
<td>60</td>
<td>70</td>
<td>65</td>
<td>75</td>
<td>66</td>
<td>78</td>
<td>68</td>
</tr>
<tr>
<td>No. patients</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
</tr>
</tbody>
</table>

Figure 2. Kazerouni score fluctuations during cyclosporine treatment.

Figure 3. Forced vital capacity (top) and DLCO (bottom) fluctuations in patients with usual interstitial pneumonia during followup (expressed as percentage of theoretical value).
The effectiveness of CYC in this setting 40, but the lack of PFT relapse. However, there is 1 study that did not confirm the role in the appearance of different manifestations (ILD in particular) in a murine model of antisynthetase syndrome48. Data in the literature indicate that autoreactive Jo1-specific T cells play a primary role in the appearance of different manifestations (ILD in particular) in a murine model of antisynthetase syndrome48. Moreover, CYC could also inhibit nuclear factor-κB (NF-κB)49,50,51, a transcription factor family that transmits signals from the cell surface to the nucleus, resulting in transcriptional effects on the genes involved in inflammation, cell differentiation, and survival52. NF-κB complex has been associated with the appearance of idiopathic inflammatory myopathies in general and with DM in particular53, which is similar to antisynthetase syndrome. Further, the inhibition of NF-κB in an experimental murine model of chronic lung fibrosis led to reduction of collagen deposition and lung injury in both acute and chronic phases54.

Studies have reported CYC involvement in the down-regulation of tumor necrosis factor-α and the upregulation of interleukin 10 in several conditions55,56,57,58. Taking into account the genetically determined imbalance of serum levels of tumor necrosis factor-α and interleukin 10 in anti-Jo1 patients59, these mechanisms could also explain the efficacy of CYC in this setting.

We are aware of the limitations of this work. The main criticism is that it is a single-center study and is therefore open to the risk of selection bias. Our study is neither prospective nor placebo-controlled and is limited by the small number of patients evaluated.

Despite the limitations, our results suggest that CYC is useful for both induction and longterm maintenance of remission in antisynthetase syndrome patients with corticosteroid-refractory ILD. It is conceivable that adding CYC to corticosteroids shortly after onset of ILD may be effective in disease control. Further comparative studies involving a larger cohort of patients are needed to confirm our results.

**REFERENCES**


**Table 3.** Main studies/case reports evaluating effectiveness of calcineurin inhibitors (cyclosporine and tacrolimus) in antisynthetase patients with ILD.

<table>
<thead>
<tr>
<th>Study</th>
<th>No. Pts Assessed</th>
<th>No. Anti-Jo-1 Pts</th>
<th>Immunosuppressant</th>
<th>Followup on Immunosuppressants, mo</th>
<th>Patients Improved</th>
<th>ILD Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present study</td>
<td>17</td>
<td>17</td>
<td>Cyclosporine</td>
<td>96**</td>
<td>17/17</td>
<td>FVC, DLCO</td>
</tr>
<tr>
<td>Sauty29</td>
<td>4</td>
<td>4</td>
<td>Cyclosporine (+ azathioprine)</td>
<td>18**</td>
<td>4/4</td>
<td>TLC, FVC, DLCO</td>
</tr>
<tr>
<td>Tellus27</td>
<td>1</td>
<td>1</td>
<td>Cyclosporine</td>
<td>60</td>
<td>1/1</td>
<td>FVC, DLCO</td>
</tr>
<tr>
<td>Wilkes14</td>
<td>12</td>
<td>12</td>
<td>Tacrolimus</td>
<td>36**</td>
<td>12/12</td>
<td>FVC, DLCO</td>
</tr>
<tr>
<td>Guglielmi25</td>
<td>1</td>
<td>1</td>
<td>Tacrolimus</td>
<td>6</td>
<td>1/1</td>
<td>NA</td>
</tr>
<tr>
<td>Koreeda30</td>
<td>5‡</td>
<td>5</td>
<td>Cyclosporine</td>
<td>14**</td>
<td>4/5</td>
<td>Yes†</td>
</tr>
<tr>
<td>Ingegnoli30†</td>
<td>7‡†</td>
<td>7</td>
<td>Cyclosporine</td>
<td>12</td>
<td>0/7</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Other 9 patients not taking cyclosporine. ** Median. † Data not further specified. ‡ Eight other patients taking cyclophosphamide. ILD: interstitial lung disease; PFT: pulmonary function tests; HRCT: high-resolution computed tomography; FVC: forced vital capacity; TLC: total lung capacity; NA: not available.